The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19

Harsh Shah, Md Shahjalal Hossain Khan, Nikhil V. Dhurandhar, Vijay Hegde

Research output: Contribution to journalReview articlepeer-review

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a pandemic. The cellular receptor for SARS-CoV-2 entry is the angiotensin-converting enzyme 2, a membrane-bound homolog of angiotensin-converting enzyme. Henceforth, this has brought the attention of the scientific community to study the interaction between COVID-19 and the renin–angiotensin system (RAS), as well as RAS inhibitors. However, these inhibitors are commonly used to treat hypertension, chronic kidney disorder, and diabetes. Obesity is a known risk factor for heart disease, diabetes, and hypertension, whereas diabetes and hypertension may be indirectly related to each other through the effects of obesity. Furthermore, people with hypertension, obesity, diabetes, and other related complications like cardiovascular and kidney diseases have a higher risk of severe COVID-19 infection than the general population and usually exhibit poor prognosis. This severity could be due to systemic inflammation and compromised immune response and RAS associated with these comorbid conditions. Therefore, there is an urgent need to develop evidence-based treatment methods that do not affect the severity of COVID-19 infection and effectively manage these chronic diseases in people with COVID-19.

Original languageEnglish
JournalActa Diabetologica
DOIs
StateAccepted/In press - 2021

Keywords

  • ACE2
  • Comorbidities
  • SARS-CoV-2
  • Viral infection

Fingerprint Dive into the research topics of 'The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19'. Together they form a unique fingerprint.

Cite this